Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles

Eui Joon Cha, Eue Soon Jang, In Cheol Sun, In Joon Lee, Jeong Hoon Ko, Young Il Kim, Ick Chan Kwon, Kwang Meyung Kim, Cheol Hee Ahn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A fabrication method of Cy5.5-MMP substrate and PEG conjugated iron oxide nanoparticles with thin silica coating (PCM-CS) and its potential as an 'activatable' dual imaging probe for tumor imaging is described in this report. PCM-CS showed an intensity-averaged diameter of 43.1 ± 6.3 nm by dynamic light scattering without any noticeable aggregation over 7 days. Fluorescence of Cy5.5 on the surface of nanoparticles was fully quenched and the quenching efficiency was 97.2%. PCM-CS showed protease specific fluorescence recovery in vitro caused from the specific peptide cleavage by MMP-2 and the probe displayed the sensitivity on 0.5 nM or less enzyme concentration. Tumor was successfully visualized by NIRF and MRI in vivo by intravenously injected PCM-CS. NIRF signal of tumor was gradually increased up to 12 h post injection and the intensity of tumor was about 3-4 times higher than normal tissue. NIRF signal at MMP-2 inhibitor treated tumor was clearly lower than tumor without inhibitor due to the insufficient peptide cleavage. NIRF signal at excised tumor was 5-10 times stronger than other organs. Noticeable darkening in magnetic resonance image was observed at the tumor region and the image was gradually darkened at 12 h post injection of PCM-CS. The maximum signal difference between tumor region and healthy muscle was 34%.

Original languageEnglish
Pages (from-to)152-158
Number of pages7
JournalJournal of Controlled Release
Volume155
Issue number2
DOIs
Publication statusPublished - 2011 Oct 30
Externally publishedYes

Fingerprint

Multimodal Imaging
Nanoparticles
Neoplasms
Matrix Metalloproteinases
Fluorescence
ferric oxide
Peptides
Injections
Matrix Metalloproteinase Inhibitors
Silicon Dioxide
Peptide Hydrolases
Magnetic Resonance Spectroscopy

Keywords

  • Activatable
  • Core-shell nanoparticle
  • Dual imaging
  • Iron oxide
  • MRI
  • Optical imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cha, E. J., Jang, E. S., Sun, I. C., Lee, I. J., Ko, J. H., Kim, Y. I., ... Ahn, C. H. (2011). Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. Journal of Controlled Release, 155(2), 152-158. https://doi.org/10.1016/j.jconrel.2011.07.019

Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. / Cha, Eui Joon; Jang, Eue Soon; Sun, In Cheol; Lee, In Joon; Ko, Jeong Hoon; Kim, Young Il; Kwon, Ick Chan; Kim, Kwang Meyung; Ahn, Cheol Hee.

In: Journal of Controlled Release, Vol. 155, No. 2, 30.10.2011, p. 152-158.

Research output: Contribution to journalArticle

Cha, Eui Joon ; Jang, Eue Soon ; Sun, In Cheol ; Lee, In Joon ; Ko, Jeong Hoon ; Kim, Young Il ; Kwon, Ick Chan ; Kim, Kwang Meyung ; Ahn, Cheol Hee. / Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. In: Journal of Controlled Release. 2011 ; Vol. 155, No. 2. pp. 152-158.
@article{c6c4ec042854491dada8f2dfd8dfd929,
title = "Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles",
abstract = "A fabrication method of Cy5.5-MMP substrate and PEG conjugated iron oxide nanoparticles with thin silica coating (PCM-CS) and its potential as an 'activatable' dual imaging probe for tumor imaging is described in this report. PCM-CS showed an intensity-averaged diameter of 43.1 ± 6.3 nm by dynamic light scattering without any noticeable aggregation over 7 days. Fluorescence of Cy5.5 on the surface of nanoparticles was fully quenched and the quenching efficiency was 97.2{\%}. PCM-CS showed protease specific fluorescence recovery in vitro caused from the specific peptide cleavage by MMP-2 and the probe displayed the sensitivity on 0.5 nM or less enzyme concentration. Tumor was successfully visualized by NIRF and MRI in vivo by intravenously injected PCM-CS. NIRF signal of tumor was gradually increased up to 12 h post injection and the intensity of tumor was about 3-4 times higher than normal tissue. NIRF signal at MMP-2 inhibitor treated tumor was clearly lower than tumor without inhibitor due to the insufficient peptide cleavage. NIRF signal at excised tumor was 5-10 times stronger than other organs. Noticeable darkening in magnetic resonance image was observed at the tumor region and the image was gradually darkened at 12 h post injection of PCM-CS. The maximum signal difference between tumor region and healthy muscle was 34{\%}.",
keywords = "Activatable, Core-shell nanoparticle, Dual imaging, Iron oxide, MRI, Optical imaging",
author = "Cha, {Eui Joon} and Jang, {Eue Soon} and Sun, {In Cheol} and Lee, {In Joon} and Ko, {Jeong Hoon} and Kim, {Young Il} and Kwon, {Ick Chan} and Kim, {Kwang Meyung} and Ahn, {Cheol Hee}",
year = "2011",
month = "10",
day = "30",
doi = "10.1016/j.jconrel.2011.07.019",
language = "English",
volume = "155",
pages = "152--158",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles

AU - Cha, Eui Joon

AU - Jang, Eue Soon

AU - Sun, In Cheol

AU - Lee, In Joon

AU - Ko, Jeong Hoon

AU - Kim, Young Il

AU - Kwon, Ick Chan

AU - Kim, Kwang Meyung

AU - Ahn, Cheol Hee

PY - 2011/10/30

Y1 - 2011/10/30

N2 - A fabrication method of Cy5.5-MMP substrate and PEG conjugated iron oxide nanoparticles with thin silica coating (PCM-CS) and its potential as an 'activatable' dual imaging probe for tumor imaging is described in this report. PCM-CS showed an intensity-averaged diameter of 43.1 ± 6.3 nm by dynamic light scattering without any noticeable aggregation over 7 days. Fluorescence of Cy5.5 on the surface of nanoparticles was fully quenched and the quenching efficiency was 97.2%. PCM-CS showed protease specific fluorescence recovery in vitro caused from the specific peptide cleavage by MMP-2 and the probe displayed the sensitivity on 0.5 nM or less enzyme concentration. Tumor was successfully visualized by NIRF and MRI in vivo by intravenously injected PCM-CS. NIRF signal of tumor was gradually increased up to 12 h post injection and the intensity of tumor was about 3-4 times higher than normal tissue. NIRF signal at MMP-2 inhibitor treated tumor was clearly lower than tumor without inhibitor due to the insufficient peptide cleavage. NIRF signal at excised tumor was 5-10 times stronger than other organs. Noticeable darkening in magnetic resonance image was observed at the tumor region and the image was gradually darkened at 12 h post injection of PCM-CS. The maximum signal difference between tumor region and healthy muscle was 34%.

AB - A fabrication method of Cy5.5-MMP substrate and PEG conjugated iron oxide nanoparticles with thin silica coating (PCM-CS) and its potential as an 'activatable' dual imaging probe for tumor imaging is described in this report. PCM-CS showed an intensity-averaged diameter of 43.1 ± 6.3 nm by dynamic light scattering without any noticeable aggregation over 7 days. Fluorescence of Cy5.5 on the surface of nanoparticles was fully quenched and the quenching efficiency was 97.2%. PCM-CS showed protease specific fluorescence recovery in vitro caused from the specific peptide cleavage by MMP-2 and the probe displayed the sensitivity on 0.5 nM or less enzyme concentration. Tumor was successfully visualized by NIRF and MRI in vivo by intravenously injected PCM-CS. NIRF signal of tumor was gradually increased up to 12 h post injection and the intensity of tumor was about 3-4 times higher than normal tissue. NIRF signal at MMP-2 inhibitor treated tumor was clearly lower than tumor without inhibitor due to the insufficient peptide cleavage. NIRF signal at excised tumor was 5-10 times stronger than other organs. Noticeable darkening in magnetic resonance image was observed at the tumor region and the image was gradually darkened at 12 h post injection of PCM-CS. The maximum signal difference between tumor region and healthy muscle was 34%.

KW - Activatable

KW - Core-shell nanoparticle

KW - Dual imaging

KW - Iron oxide

KW - MRI

KW - Optical imaging

UR - http://www.scopus.com/inward/record.url?scp=80054092195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054092195&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2011.07.019

DO - 10.1016/j.jconrel.2011.07.019

M3 - Article

C2 - 21801769

AN - SCOPUS:80054092195

VL - 155

SP - 152

EP - 158

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -